Breaking News

Yesterday Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Periodicals	Germany expects AstraZeneca to deliver 3M vaccine doses in February,Reuters says » 15:30 01/24/21 01/24 15:30 01/24/21 15:30 AZN AstraZeneca $53.26 / +0.73 (+1.39%) Germany expects… Germany expects AstraZeneca to deliver 3M doses of its COVID-19 vaccine in February despite the company's latest production problems, Health Minister Jens Spahn told Bild am Sonntag newspaper. AstraZeneca informed European Union officials it would cut deliveries of its COVID-19 vaccine to the bloc by 60% to 31M doses in the first quarter of the year due to production problems, a senior official told Reuters. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.26 / +0.73 (+1.39%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.26 / +0.73 (+1.39%) 01/22/21 Barclays AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations AZN AstraZeneca $53.26 / +0.73 (+1.39%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.26 / +0.73 (+1.39%) 01/22/21 AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says 01/22/21 EU to see delay of AstraZeneca COVID vaccine delivery, FT reports 01/22/21 AstraZeneca informs EU Commission of vaccine delivery issues, Bild says 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says AZN AstraZeneca $53.26 / +0.73 (+1.39%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.26 / +0.73 (+1.39%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish

Friday
Periodicals	J&J director says company could boost vaccine availability by spring, CNBC says » 16:18 01/22/21 01/22 16:18 01/22/21 16:18 JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) Johnson & Johnson… Johnson & Johnson board member Dr. Mark McClellan said that "if the clinical trial works out," the company may be able to significantly boost America's COVID-19 vaccine supply availability within a matter of weeks, CNBC's Emily DeCiccio reports. I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," said the former FDA Commissioner in a Thursday evening interview on CNBC. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/21/21 Addex Therapeutics receives IND approval to start study in epilepsy 01/19/21 Royalty Pharma acquires royalty interest in Seltorexant from Minerva 01/19/21 Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 01/15/21 B. Riley Securities Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 12/29/20 Piper Sandler Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 01/13/21 Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says 01/13/21 J&J chief science officer sees possible vaccine approval by March, Reuters says 01/13/21 J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says 01/13/21 EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 01/14/21 Fly Intel: Wall Street's top stories for Thursday 01/14/21 Fly Intel: Wall Street's top stories at midday 01/13/21 Fly Intel: Wall Street's top stories for Wednesday 12/29/20 Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades 03/01/21 41st Annual Healthcare Virtual Conference 01/26/21 Johnson & Johnson - JNJ JNJ Johnson & Johnson $163.68 / +1.99 (+1.23%) 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th
Periodicals	AstraZeneca to slash EU COVID-19 vaccine deliveries by 60% in Q1, Reuters says » 15:25 01/22/21 01/22 15:25 01/22/21 15:25 AZN AstraZeneca $53.21 / +0.68 (+1.29%) AstraZeneca has informed… AstraZeneca has informed European Union officials that it would reduce deliveries of its coronavirus vaccine to the bloc by 60% to 31M doses in the first quarter of 2021 due to production issues, Reuters' Francesco Guarascio reports, citing a senior official. The company was forecast to deliver to the 27 EU countries roughly 80M shots by the end of March, the author notes, citing the official who was involved in the talks. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.21 / +0.68 (+1.29%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.21 / +0.68 (+1.29%) 01/22/21 Barclays AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations AZN AstraZeneca $53.21 / +0.68 (+1.29%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.21 / +0.68 (+1.29%) 01/22/21 EU to see delay of AstraZeneca COVID vaccine delivery, FT reports 01/22/21 AstraZeneca informs EU Commission of vaccine delivery issues, Bild says 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports AZN AstraZeneca $53.21 / +0.68 (+1.29%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.21 / +0.68 (+1.29%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Recommendations	AstraZeneca price target lowered to 9,000 GBp from 9,300 GBp at Barclays » 15:00 01/22/21 01/22 15:00 01/22/21 15:00 AZN AstraZeneca $53.30 / +0.77 (+1.47%) Barclays analyst Emmanuel… Barclays analyst Emmanuel Papadakis lowered the firm's price target on AstraZeneca to 9,000 GBp from 9,300 GBp and keeps an Overweight rating on the shares. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.30 / +0.77 (+1.47%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.30 / +0.77 (+1.47%) 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank AZN AstraZeneca $53.30 / +0.77 (+1.47%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.30 / +0.77 (+1.47%) 01/22/21 EU to see delay of AstraZeneca COVID vaccine delivery, FT reports 01/22/21 AstraZeneca informs EU Commission of vaccine delivery issues, Bild says 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports AZN AstraZeneca $53.30 / +0.77 (+1.47%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.30 / +0.77 (+1.47%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Hot Stocks	Pfizer, BioNTech reach agreement with COVAX for advance purchase of vaccine » 12:02 01/22/21 01/22 12:02 01/22/21 12:02 PFE Pfizer $36.47 / -0.02 (-0.05%) , BNTX BioNTech $106.21 / +0.87 (+0.83%) Pfizer (PFE) and BioNTech… Pfizer (PFE) and BioNTech (BNTX) announced an advance purchase agreement with COVAX for up to 40 million doses of the Pfizer-BioNTech COVID-19 Vaccine. The doses will be delivered throughout 2021. COVAX is a global initiative coordinated by the Global Alliance for Vaccines and Immunization, the Coalition for Epidemic Preparedness Innovations and the World Health Organization, to ensure equitable access to COVID-19 vaccines for all countries, regardless of income levels. COVAX includes an Advanced Market Commitment financial mechanism that aims to ensure that 92 low- and lower-middle-income countries will be able to secure access to COVID-19 vaccines at the same time as higher-income countries. The first doses are expected to be delivered in the first quarter of 2021, subject to the negotiation and execution of supply agreements under the COVAX Facility structure. For the COVAX Advanced Market Commitment 92 countries, Pfizer and BioNTech will provide the vaccine to COVAX at a not-for-profit price. Financial terms of the agreement were not disclosed. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 01/22/21 Coty promotes Stephane Delbos to chief procurement officer 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus BNTX BioNTech $106.21 / +0.87 (+0.83%) 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/07/21 BioNTech reports publication of preclinical data on novel mRNA vaccine approach PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg BNTX BioNTech $106.21 / +0.87 (+0.83%) 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 BNTX BioNTech $106.21 / +0.87 (+0.83%) 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate 23 Jul 06 Feb PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports BNTX BioNTech $106.21 / +0.87 (+0.83%) 01/20/21 Pfizer/BioNTech vaccine likely to be effective against Covid variant, FT reports PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday BNTX BioNTech $106.21 / +0.87 (+0.83%) 01/05/21 Fly Intel: Wall Street's top stories for Tuesday 01/05/21 Fly Intel: Wall Street's top stories at midday 02/08/21 17th Annual Virtual WORLDSymposium 2021 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/02/21 Pfizer - PFE 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 PFE BNTX PFE Pfizer $36.47 / -0.02 (-0.05%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th BNTX BioNTech $106.21 / +0.87 (+0.83%) 01/19/21 Largest borrow rate increases among liquid names 11/23/20 Largest borrow rate increases among liquid names 11/20/20 Unusually active option classes on open November 20th 11/02/20 Largest borrow rate increases among liquid names

Periodicals	EU to see delay of AstraZeneca COVID vaccine delivery, FT reports » 11:53 01/22/21 01/22 11:53 01/22/21 11:53 AZN AstraZeneca $53.07 / +0.54 (+1.03%) The European Union will… The European Union will experience a delay in the delivery of COVID-19 vaccines made by AstraZeneca in partnership with Oxford, the Financial Times reports. The company said that initial volumes of the vaccine will be "lower than originally anticipated," the report says. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.07 / +0.54 (+1.03%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.07 / +0.54 (+1.03%) 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank AZN AstraZeneca $53.07 / +0.54 (+1.03%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.07 / +0.54 (+1.03%) 01/22/21 AstraZeneca informs EU Commission of vaccine delivery issues, Bild says 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports 01/03/21 AstraZeneca/Oxford COVID vaccine authorized by India, WSJ reports AZN AstraZeneca $53.07 / +0.54 (+1.03%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.07 / +0.54 (+1.03%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Periodicals	AstraZeneca informs EU Commission of vaccine delivery issues, Bild says » 10:38 01/22/21 01/22 10:38 01/22/21 10:38 AZN AstraZeneca $53.02 / +0.49 (+0.93%) A translation of a… A translation of a German-language report from Bild indicates that AstraZeneca has informed the EU Commission that it will initially be able to deliver significantly less of the Oxford vaccine for COVID-19 after approval than had been anticipated. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AZN AstraZeneca $53.02 / +0.49 (+0.93%) 01/20/21 AstraZeneca's Enhertu approved in EU for HER2-positive metastatic breast cancer 01/18/21 AstraZeneca, Daiichi announce FDA approval of Enhertu for gastric cancer 01/15/21 Aveo Pharmaceuticals announces results from portion of DEDUCTIVE trial 01/15/21 AstraZeneca's Imfinzi approved in E.U. and U.K. for additional dosing in NSCLC AZN AstraZeneca $53.02 / +0.49 (+0.93%) 01/19/21 BTIG Adaptive Biotechnologies price target raised to $74 from $66 at BTIG 01/15/21 Berenberg AstraZeneca price target lowered to 10,000 GBp from 10,500 GBp at Berenberg 01/15/21 Fly Intel: Top five analyst initiations 01/15/21 Deutsche Bank AstraZeneca initiated with a Buy at Deutsche Bank AZN AstraZeneca $53.02 / +0.49 (+0.93%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER AZN AstraZeneca $53.02 / +0.49 (+0.93%) 01/17/21 Pakistan approves AstraZeneca COVID vaccine for emergency use, Reuters says 01/15/21 AstraZeneca's COVISHIELD vaccine approved by Nepal, Reuters reports 01/03/21 AstraZeneca/Oxford COVID vaccine authorized by India, WSJ reports 12/30/20 U.S. EUA for AstraZeneca's COVID vaccine likely in April, Reuters reports AZN AstraZeneca $53.02 / +0.49 (+0.93%) 12/30/20 Fly Intel: Wall Street's top stories for Wednesday 12/30/20 Fly Intel: Wall Street's top stories at midday 12/30/20 AstraZeneca upgrade, Spotify target change among top calls on Wall Street 12/30/20 Fly Intel: Pre-market Movers 01/26/21 Pharmacovigilance & Risk Management Strategies Virtual Conference 01/28/21 IASLC Virtual World Conference on Lung Cancer 03/01/21 41st Annual Healthcare Virtual Conference 03/02/21 2021 London Global Healthcare Virtual Conference 02/20/21 PDUFA Date for Tagrisso (Osimertinib) 03/20/21 PDUFA Date for Roxadustat--Extended Date 05/06/21 FARXIGA Granted Priority Review for Chronic Kidney Disease AZN AstraZeneca $53.02 / +0.49 (+0.93%) 12/30/20 Unusually active option classes on open December 30th 12/29/20 Unusually active option classes on open December 29th 12/28/20 Unusually active option classes on open December 28th 12/14/20 AstraZeneca call volume above normal and directionally bullish
Hot Stocks	Coty promotes Stephane Delbos to chief procurement officer » 08:20 01/22/21 01/22 08:20 01/22/21 08:20 COTY Coty $6.88 / -0.01 (-0.15%) , PFE Pfizer $36.49 / +0.01 (+0.03%) Coty (COTY) announced the… Coty (COTY) announced the promotion of Stephane Delbos to chief procurement officer, or CPO, effective February 1. Delbos, who joined Coty in 2010 as global sourcing director, has been promoted from his current role as senior VP for transformation, indirect and procurement operations, where he has played an important role in driving forward Coty's broader transformation agenda. Delbos will join Coty's senior leadership team and report to Gordon von Bretten, chief transformation officer. Delbos is a senior procurement professional with over 18 years' experience in the beauty and pharmaceutical industries. Prior to joining Coty, he held several local and global procurement positions at Pfizer (PFE). In his new role, Delbos will be responsible for implementing Coty's multi-year procurement strategy, which includes achieving a significant cost reduction target by FY23, reducing complexity and strengthening Coty's new product pipeline. This forms an important element of Coty's transformation program, announced in 2020. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE COTY PFE Pfizer $36.49 / +0.01 (+0.03%) 01/21/21 ViiV Healthcare announces FDA approval of Cabenuva 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori COTY Coty $6.88 / -0.01 (-0.15%) 12/09/20 Coty CFO Pierre-Andre Terisse to switch roles, Laurent Mercier to succeed 11/27/20 Coty falls -8.5% 11/19/20 Coty rises 13.5% 11/06/20 Coty rises 23.0% COTY PFE COTY Coty $6.88 / -0.01 (-0.15%) 12/07/20 Wells Fargo Coty downgraded to Underweight from Equal Weight at Wells Fargo 11/19/20 Fly Intel: Top five analyst upgrades 11/19/20 Citi Coty upgraded to Buy from Neutral at Citi 11/09/20 Deutsche Bank Coty price target raised to $6 from $4 at Deutsche Bank PFE Pfizer $36.49 / +0.01 (+0.03%) 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg PFE COTY PFE Pfizer $36.49 / +0.01 (+0.03%) 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 COTY Coty $6.88 / -0.01 (-0.15%) 11/06/20 Coty reports Q1 adjusted EPS 11c, consensus (5c) 08/27/20 Coty reports Q4 adjusted cont ops EPS (46c), consensus (11c) 08/27/20 Coty reports Q4 adjusted EPS (51c), consensus (11c) 08/26/20 Notable companies reporting before tomorrow's open PFE PFE Pfizer $36.49 / +0.01 (+0.03%) 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports PFE COTY PFE Pfizer $36.49 / +0.01 (+0.03%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday COTY Coty $6.88 / -0.01 (-0.15%) 11/30/20 Fly Insider: Merrimack, Catalent among weeks notable insider trades 10/07/20 Fly Intel: After-Hours Movers 10/07/20 JetBlue double upgrade among today's top calls on Wall Street 10/07/20 Fly Intel: Pre-market Movers 02/08/21 17th Annual Virtual WORLDSymposium 2021 03/01/21 41st Annual Healthcare Virtual Conference 02/02/21 Pfizer - PFE 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 PFE COTY PFE Pfizer $36.49 / +0.01 (+0.03%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th COTY Coty $6.88 / -0.01 (-0.15%) 12/22/20 Coty call volume above normal and directionally bullish 11/30/20 Coty call volume above normal and directionally bullish 11/25/20 Unusually active option classes on open November 25th 11/19/20 Coty call volume above normal and directionally bullish

Thursday
Hot Stocks	ViiV Healthcare announces FDA approval of Cabenuva » 16:46 01/21/21 01/21 16:46 01/21/21 16:46 GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) , PFE Pfizer $36.49 / +0.01 (+0.03%) , JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) ViiV Healthcare, the… ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options PFE JNJ GSK PFE Pfizer $36.49 / +0.01 (+0.03%) 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 01/21/21 Addex Therapeutics receives IND approval to start study in epilepsy 01/19/21 Royalty Pharma acquires royalty interest in Seltorexant from Minerva 01/19/21 Minerva, Royalty Pharma announce sale of seltorexant royalty for up to $155M 01/15/21 Halozyme says Janssen receives FDA approval of Darzalex Faspro GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 01/21/21 BiondVax names Amir Reichman as new CEO 01/12/21 Vir Biotechnology, GlaxoSmithKline to evaluate VIR-7832 in COVID-19 patients 01/11/21 Eligo Bioscience enters research, option agreement with GlaxoSmithKline 12/21/20 Ligand, GSK in pact 'leveraging' Icagen's small molecule 'expertise' GSK PFE JNJ GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 01/20/21 UBS GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS 01/20/21 Fly Intel: Top five analyst downgrades 01/20/21 Credit Suisse GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse 01/20/21 Credit Suisse GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse PFE Pfizer $36.49 / +0.01 (+0.03%) 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 01/15/21 B. Riley Securities Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities 12/29/20 Piper Sandler Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity PFE JNJ GSK PFE Pfizer $36.49 / +0.01 (+0.03%) 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 10/13/20 Johnson & Johnson sees 'robutst, double-digit sales growth' in 2021 10/13/20 Johnson & Johnson sees Q4 sales 'around' 2019 levels, consensus $21.52B 10/13/20 Johnson & Johnson raises FY20 adj. EPS view to $7.95-$8.05 from $7.75-$7.95 10/13/20 Johnson & Johnson reports Q3 adj. EPS $2.20, consensus $1.98 GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER PFE JNJ GSK PFE Pfizer $36.49 / +0.01 (+0.03%) 01/21/21 Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 01/13/21 Johnson & Johnson's one-dose COVID-19 vaccine appears 'promising,' CNBC says 01/13/21 J&J chief science officer sees possible vaccine approval by March, Reuters says 01/13/21 J&J sees U.S. decision on COVID-19 vaccine candidate by March, Bloomberg says 01/13/21 EU lawmaker says J&J likely to submit vaccine approval in Feb., Reuters reports GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 12/11/20 GlaxoSmithKline offered $120 per share for Eidos Therapeutics, Bloomberg says PFE JNJ GSK PFE Pfizer $36.49 / +0.01 (+0.03%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 01/14/21 Fly Intel: Wall Street's top stories for Thursday 01/14/21 Fly Intel: Wall Street's top stories at midday 01/13/21 Fly Intel: Wall Street's top stories for Wednesday 12/29/20 Street Fight: Citi sees opportunity in Arcturus as COVID data prompts downgrades GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday 01/21/21 Healthcare 02/08/21 17th Annual Virtual WORLDSymposium 2021 03/02/21 2021 London Global Healthcare Virtual Conference 01/26/21 Johnson & Johnson - JNJ 02/02/21 Pfizer - PFE 02/03/21 GlaxoSmithKline - GSK 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 PFE JNJ GSK PFE Pfizer $36.49 / +0.01 (+0.03%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th JNJ Johnson & Johnson $161.69 / -0.71 (-0.44%) 12/01/20 Johnson & Johnson call volume above normal and directionally bullish 10/13/20 Unusually active option classes on open October 13th 09/23/20 Unusually active option classes on open September 23rd 08/24/20 Unusually active option classes on open August 24th GSK GlaxoSmithKline $37.79 / -0.23 (-0.60%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st
Periodicals	Pfizer slashes vaccine deliveries to some EU countries by 50%, Reuters reports » 15:21 01/21/21 01/21 15:21 01/21/21 15:21 PFE Pfizer $36.45 / -0.035 (-0.10%) , BNTX BioNTech $107.01 / +3.71 (+3.59%) Pfizer (PFE) has cut in… Pfizer (PFE) has cut in half the volume of COVID-19 vaccines it will deliver to some EU countries this week, Reuters' Radu-Sorin Marinas, Jan Lopatka, and Tsvetelia Tsolova report, citing government officials. Pfizer and its partner BioNTech (BNTX) have declined to comment on the cuts beyond their statement last week, the report noted. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 01/21/21 Cerevel Therapeutics appoints Deval Patrick, Deborah Baron to board 01/20/21 Pfizer, BioNTech: COVID-19 vaccine elicits antibodies neutralizing pseudovirus 01/14/21 Pfizer says FDA approves supplemental NDA for Xalkori 01/14/21 Oragenics issues letter to stockholders on Terra CoV-2 BNTX BioNTech $107.01 / +3.71 (+3.59%) 01/12/21 Canada orders 20M more doses of Pfizer, BioNTech Covid vaccine 01/08/21 Pfizer, BioNTech COVID vaccine elicits antibodies that neutralize mutation 01/07/21 BioNTech reports publication of preclinical data on novel mRNA vaccine approach PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 01/14/21 Morgan Stanley 80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley 01/14/21 Oppenheimer Essa Pharma price target raised to $20 from $9 at Oppenheimer 01/05/21 Argus Viatris initiated with a Hold at Argus 12/31/20 Ladenburg UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg BNTX BioNTech $107.01 / +3.71 (+3.59%) 12/29/20 Citi Arcturus selloff brings 'very good' buying opportunity, says Citi 12/22/20 Roth Capital Translate Bio price target raised to $37 from $30 at Roth Capital 12/15/20 Jefferies Jefferies starts Maravai at Buy, says 'more than just a COVID vaccine play' PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 01/12/21 Pfizer sees FY21 EPS around $3.00-$3.10, consensus $3.07 10/27/20 Pfizer sees FY20 Upjohn revenue $8B-$8.5B, adjusted EBITDA $3.8B-$4.2B 10/27/20 Pfizer sees FY20 adjusted EPS for New Pfizer $2.28-$2.38, revenue $40.8B-$42.4B 10/27/20 Pfizer narrows FY20 adjusted EPS view to $2.88-$2.93 from $2.85-$2.95 BNTX BioNTech $107.01 / +3.71 (+3.59%) 08/11/20 BioNTech reports Q2 EPS (EUR38c), consensus (EUR24c) 07/31/20 Pfizer, BioNTech to supply Japan with 120M doses of BNT162 vaccine candidate 23 Jul 06 Feb PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 01/21/21 Pfizer and BioNTech agree to supply vaccine to WHO co-led effort, Reuters says 01/20/21 Hong Kong set to approve COVID vaccine by Pfizer/BioNTech, SCMP says 01/20/21 Japan inks deal with Pfizer for COVID vaccine for 72M people, Nikkei reports 01/20/21 Pfizer/BioNTech vaccine likely to be effective against Covid variant, FT reports BNTX BioNTech $107.01 / +3.71 (+3.59%) 01/04/21 Pfizer, BioNTech offered South Africa discounted vaccines, Bloomberg says PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 01/12/21 Fly Intel: Wall Street's top stories for Tuesday 01/12/21 Fly Intel: Wall Street's top stories at midday 01/08/21 Fly Intel: Wall Street's top stories for Friday 01/08/21 Fly Intel: Wall Street's top stories at midday BNTX BioNTech $107.01 / +3.71 (+3.59%) 01/05/21 Fly Intel: Wall Street's top stories for Tuesday 01/05/21 Fly Intel: Wall Street's top stories at midday 02/08/21 17th Annual Virtual WORLDSymposium 2021 03/02/21 2021 London Global Healthcare Virtual Conference 02/02/21 Pfizer - PFE 01/24/21 PDUFA Date for Xalkori (Crizotinib) - January 2021 12/29/21 PDUFA Date for Lorbrena (Lorlatinib) April 2021 PFE BNTX PFE Pfizer $36.45 / -0.035 (-0.10%) 12/15/20 Notable open interest changes for December 15th 12/14/20 Unusually active option classes on open December 14th 12/11/20 Unusually active option classes on open December 11th 12/11/20 Notable open interest changes for December 11th BNTX BioNTech $107.01 / +3.71 (+3.59%) 01/19/21 Largest borrow rate increases among liquid names 11/23/20 Largest borrow rate increases among liquid names 11/20/20 Unusually active option classes on open November 20th 11/02/20 Largest borrow rate increases among liquid names

On The Fly

News and insights, exclusive to thefly.com

20:02	Fly Intel: Top five weekend stock stories»
15:39	On The Fly: Weekly technical notes for Russell 2000»
15:39	On The Fly: Weekly technical notes for S&P 500»
09:55	Fly Intel: Top five analyst initiations»
09:55	Fly Intel: Top five analyst downgrades»

View all On The Fly Stories »

Upcoming
Events (10)

	Annual Virtual Washington DC Energy & Power Policy Field Trip
NBAC	Newborn Acquisition Corp.
USB	U.S. Bancorp
SEEL	Seelos Therapeutics
FDX	FedEx
NAVB	Navidea
	Healthcare
	MacroStrategy
	Chicago Fed National Activity Index: December 2020
	Chicago Fed National Activity Index--3 Month Moving Average: December 2020

View all of today’s events »

Today’s
Syndicate (0)

No syndicate deals.

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial